BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan ZM, Sun BC. Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol 2013; 19(47): 8895-8901 [PMID: 24379613 DOI: 10.3748/wjg.v19.i47.8895] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Cao HST, Shindoh J, Vauthey J. Primary Neoplasms of the Liver. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm092.pub2] [Reference Citation Analysis]
2 Bockmann JH, Kohsar M, Murray JM, Hamed V, Dandri M, Lüth S, Lohse AW, Schulze-Zur-Wiesch J. High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities. Microorganisms 2021;9:968. [PMID: 33946154 DOI: 10.3390/microorganisms9050968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Facciorusso A, Abd El Aziz MA, Cincione I, Cea UV, Germini A, Granieri S, Cotsoglou C, Sacco R. Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study. Biomedicines 2020;8:E399. [PMID: 33050084 DOI: 10.3390/biomedicines8100399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. Liver Transpl 2020;26:1100-11. [PMID: 32531867 DOI: 10.1002/lt.25819] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
5 Stasi C, Silvestri C, Voller F. Hepatitis B vaccination and immunotherapies: an update. Clin Exp Vaccine Res. 2020;9:1-7. [PMID: 32095435 DOI: 10.7774/cevr.2020.9.1.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 He XX, Shi LL, Qiu MJ, Li QT, Wang MM, Xiong ZF, Yang SL. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. Biochem Biophys Res Commun 2018;504:878-84. [PMID: 30219235 DOI: 10.1016/j.bbrc.2018.08.203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
7 Lee WY, Bachtiar M, Choo CCS, Lee CG. Comprehensive review of Hepatitis B Virus-associated hepatocellular carcinoma research through text mining and big data analytics. Biol Rev Camb Philos Soc. 2019;94:353-367. [PMID: 30105774 DOI: 10.1111/brv.12457] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
8 Yang Y, Zheng B, Han Q, Zhang C, Tian Z, Zhang J. Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma. Cancer Biol Ther. 2016;17:449-456. [PMID: 26934469 DOI: 10.1080/15384047.2016.1156257] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
9 Stasi C, Salomoni E, Arena U, Corti G, Montalto P, Bartalesi F, Marra F, Laffi G, Milani S, Zignego AL. Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study. Eur J Pharmacol. 2017;806:105-109. [PMID: 28414057 DOI: 10.1016/j.ejphar.2017.03.063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
10 Zhang S, Gao S, Zhao M, Liu Y, Bu Y, Jiang Q, Zhao Q, Ye L, Zhang X. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein. Cancer Lett. 2017;392:94-104. [PMID: 28192212 DOI: 10.1016/j.canlet.2017.02.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
11 Stasi C, Milani S. Evolving strategies for liver fibrosis staging: Non-invasive assessment. World J Gastroenterol 2017; 23(2): 191-196 [PMID: 28127192 DOI: 10.3748/wjg.v23.i2.191] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
12 Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016; 22(32): 7252-7263 [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
13 Yamamoto N, Yamasaki T, Takami T, Uchida K, Fujisawa K, Matsumoto T, Saeki I, Terai S, Sakaida I. Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib. J Clin Biochem Nutr. 2016;58:202-209. [PMID: 27257345 DOI: 10.3164/jcbn.15-127] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
14 Gu XQ, Zheng WP, Teng DH, Sun JS, Zheng H. Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients. World J Gastroenterol 2016; 22(9): 2749-2759 [PMID: 26973413 DOI: 10.3748/wjg.v22.i9.2749] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
15 Stasi C, Silvestri C, Voller F, Cipriani F. The epidemiological changes of HCV and HBV infections in the era of new antiviral therapies and the anti-HBV vaccine. J Infect Public Health 2016;9:389-95. [PMID: 26148849 DOI: 10.1016/j.jiph.2015.05.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
16 Zuo C, Xia M, Wu Q, Zhu H, Liu J, Liu C. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncol Lett 2015;9:527-34. [PMID: 25624883 DOI: 10.3892/ol.2014.2727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]